INHA rs2300602: Premature Ovarian Insufficiency Evidence
The rs2300602 variant is a missense alteration (c.769G>A, p.Ala257Thr) located in the inhibin subunit alpha (INHA) gene on chromosome 2. Although early genetic candidate studies proposed it as a risk factor or cause of premature ovarian insufficiency, modern population sequencing has observed it in healthy, fertile individuals. Consequently, current clinical databases generally classify the variant as benign, likely benign, or a variant of uncertain significance.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| GG | You carry two copies of the common guanine allele, encoding the standard alanine residue at position 257. This genotype is the most frequent across all global populations and represents baseline physiological inhibin alpha coding. | Informational |
| GA | You carry one copy of the common G allele and one copy of the A allele (c.769G>A, p.Ala257Thr). While historically linked to premature ovarian insufficiency in small studies, broader genomic databases show this variant is frequently found in healthy, fertile individuals. | Informational |
| AA | You carry two copies of the less common adenine allele. Contemporary evidence indicates that this homozygous genotype is present in unaffected individuals and is generally classified as benign or of uncertain significance in clinical genetic repositories. | Informational |
Genomic Location and Molecular Mechanism
The single-nucleotide polymorphism rs2300602 is situated within exon 2 of the INHA gene on chromosome 2. At the DNA level, it involves a transition from guanine to adenine at coding nucleotide 769 (c.769G>A). This single-base change results in the substitution of the amino acid alanine with threonine at codon 257 (p.Ala257Thr) in the mature peptide region of the inhibin alpha subunit. Inhibin proteins belong to the transforming growth factor-beta (TGF-beta) superfamily. Because alanine and threonine possess different biochemical side chains, laboratory research initially focused on whether this alteration disrupted normal processing, folding, or receptor interactions of the alpha chain. However, structural and bioinformatic evaluations indicate that the substitution is relatively well tolerated, and high-throughput databases record it as a tolerated or benign protein alteration.
The Biological Role of the INHA Gene
The INHA gene directs the synthesis of the alpha subunit of inhibin. Inhibins exist as heterodimeric protein complexes, consisting of an alpha subunit linked to one of two beta subunits (forming inhibin A or inhibin B). These glycoproteins are primarily synthesized in the gonads—specifically by granulosa cells in ovarian follicles and Sertoli cells in the testes. Inhibins act in a crucial endocrine negative feedback loop with the anterior pituitary gland, selectively repressing the secretion of follicle-stimulating hormone (FSH). By moderating FSH levels, inhibins ensure proper follicular development, ovulation timing, and regular menstrual cycles. Genetic disruptions that drastically impair inhibin production or signaling can disrupt this regulatory axis, which led researchers to interrogate INHA as a key candidate gene for hypergonadotropic ovarian dysfunction.
Historical Hypotheses versus Contemporary Evidence
In early candidate-gene association studies published in the early 2000s, investigators reported the rs2300602 'A' allele at elevated rates among small cohorts of individuals diagnosed with premature ovarian failure (now widely designated premature ovarian insufficiency, or POI). These early reports hypothesized that p.Ala257Thr impaired inhibin bioactivity and led directly to accelerated follicular loss. However, as large-scale population sequencing initiatives like the 1000 Genomes Project and gnomAD emerged, the A allele was repeatedly documented in unaffected individuals and fertile control cohorts across diverse ancestral backgrounds. Follow-up replication attempts yielded inconsistent and conflicting associations. Because the variant appears in healthy populations at frequencies exceeding the expected incidence of monogenic POI, modern clinical curation repositories categorize rs2300602 primarily as benign or likely benign, reflecting limited or refuted evidence of primary pathogenicity.
Clinical Interpretation and Health Context
Discovering an 'A' allele at rs2300602 on a personal genomic profile should not be taken as a diagnosis or reliable prediction of premature ovarian failure or infertility. Modern clinical genomics relies on strict ACMG/AMP criteria to evaluate variant causality, and rs2300602 fails to meet the threshold for a pathogenic variant. Premature ovarian insufficiency is an etiologically complex condition, driven by a wide array of autoimmune, chromosomal, and distinct high-penetrance genetic factors, as well as idiopathic elements. Medical guidelines recommend that diagnostic assessments for ovarian dysfunction rely on clinical symptoms, cycle tracking, and validated laboratory measurements such as elevated follicle-stimulating hormone and low estradiol, rather than screening for benign or low-penetrance candidate polymorphisms.
How common is this variant?
The minor A allele occurs at an estimated frequency of approximately 0.01 in South Asian and Middle Eastern populations, while its frequency drops below 0.005 among populations of European ancestry.
Frequently asked questions
What is INHA rs2300602?
INHA rs2300602 is a single-nucleotide polymorphism in the inhibin subunit alpha gene that causes a missense change (p.Ala257Thr). Although researchers once considered it a primary candidate mutation for premature ovarian insufficiency, modern evidence indicates it is a non-pathogenic variant present in healthy individuals.
Does having the rs2300602 A allele mean I will experience premature menopause?
No, carrying the A allele does not mean you will develop premature menopause or premature ovarian insufficiency. Population genetic studies have shown that this variant is found in many fertile individuals without reproductive disorders, leading clinical geneticists to consider it benign or of uncertain significance.
Why did early research think rs2300602 caused ovarian failure?
Early studies relied on small cohorts of patients and limited control datasets, leading to apparent statistical associations that failed to hold up in larger, more diverse genetic studies. When comprehensive population databases such as gnomAD were assembled, the variant was found frequently enough in the general population to cast doubt on its pathogenicity.
What should I do if my genetic data shows this variant?
No medical intervention is indicated based solely on this genotype. If you have concerns about your fertility, irregular periods, or early menopause, you should discuss clinical testing—such as hormone level measurements—with an endocrinologist or reproductive specialist.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2300602?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29